Head to Head Comparison: Inhibrx Biosciences (NASDAQ:INBX) versus BioMarin Pharmaceutical (NASDAQ:BMRN)

Inhibrx Biosciences (NASDAQ:INBX) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership.

Insider & Institutional Ownership

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Inhibrx Biosciences and BioMarin Pharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1	2	2	1	2.50
BioMarin Pharmaceutical	1	6	14	2	2.74

Inhibrx Biosciences presently has a consensus target price of $197.50, indicating a potential upside of 72.73%. BioMarin Pharmaceutical has a consensus target price of $89.17, indicating a potential upside of 37.98%. Given Inhibrx Biosciences’ higher probable upside, equities research analysts clearly believe Inhibrx Biosciences is more favorable than BioMarin Pharmaceutical.

Profitability

This table compares Inhibrx Biosciences and BioMarin Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-83.48%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Valuation & Earnings

This table compares Inhibrx Biosciences and BioMarin Pharmaceutical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	N/A	N/A	-$140.05 million	($8.88)	-12.88
BioMarin Pharmaceutical	$3.22 billion	3.88	$348.90 million	$0.37	174.68

BioMarin Pharmaceutical has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Inhibrx Biosciences has a beta of 3.66, meaning that its stock price is 266% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500.

Summary

BioMarin Pharmaceutical beats Inhibrx Biosciences on 11 of the 14 factors compared between the two stocks.

About Inhibrx Biosciences

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.